Global Novel Oral AntiCoagulants (NOAC) Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Novel Oral AntiCoagulants (NOAC) Market Research Report 2024
Anticoagulants, commonly referred to as blood thinners, are substances that prevent or reduce coagulation of blood, prolonging the clotting time. Some of them occur naturally in blood-eating animals such as leeches and mosquitoes, where they help keep the bite area unclotted long enough for the animal to obtain some blood. As a class of medications, anticoagulants are used in therapy for thrombotic disorders. Oral anticoagulants (OACs) are taken by many people in pill or tablet form, and various intravenous anticoagulant dosage forms are used in hospitals. Some anticoagulants are used in medical equipment, such as test tubes, serum-separating tubes, blood transfusion bags, and dialysis equipment.
According to Mr Accuracy reports’s new survey, global Novel Oral AntiCoagulants (NOAC) market is projected to reach US$ million in 2034, increasing from US$ million in 2024, with the CAGR of % during the period of 2023 to 2034. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Novel Oral AntiCoagulants (NOAC) market research.
Market competition is intense. Sanofi, Bristol-Myers Squibb, Bayer, Johnson & Johnson, Genentech (Roche) and Boehringer Ingelheim etc. are the leaders of the industry, with about 64% market shares.
North America is the largest consumption place, with a consumption market share nearly 39%. Following North America, Europe is the second largest consumption place with the consumption market share of 26%.
Report Scope
This report, based on historical analysis (2018-2024) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Novel Oral AntiCoagulants (NOAC) market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Johnson & Johnson
Bristol-Myers Squibb
Boehringer Ingelheim
Sanofi
Daiichi Sankyo
Armatheon
Aspen
AstraZeneca
Bayer
Cellceutix
Cosmo Pharmaceuticals
CSL Behring
Eisai
GSK
Marathon Pharmaceuticals
Ockham Biotech
Perosphere
Segment by Type
Direct Thrombin Inhibitors
Direct Factor Xa Inhibitors
Deep Vein Thrombosis (DVT)
Pulmonary Embolism
Acute Coronary Syndrome
Hemodialysis
Others
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Novel Oral AntiCoagulants (NOAC) report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
According to Mr Accuracy reports’s new survey, global Novel Oral AntiCoagulants (NOAC) market is projected to reach US$ million in 2034, increasing from US$ million in 2024, with the CAGR of % during the period of 2023 to 2034. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Novel Oral AntiCoagulants (NOAC) market research.
Market competition is intense. Sanofi, Bristol-Myers Squibb, Bayer, Johnson & Johnson, Genentech (Roche) and Boehringer Ingelheim etc. are the leaders of the industry, with about 64% market shares.
North America is the largest consumption place, with a consumption market share nearly 39%. Following North America, Europe is the second largest consumption place with the consumption market share of 26%.
Report Scope
This report, based on historical analysis (2018-2024) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Novel Oral AntiCoagulants (NOAC) market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Johnson & Johnson
Bristol-Myers Squibb
Boehringer Ingelheim
Sanofi
Daiichi Sankyo
Armatheon
Aspen
AstraZeneca
Bayer
Cellceutix
Cosmo Pharmaceuticals
CSL Behring
Eisai
GSK
Marathon Pharmaceuticals
Ockham Biotech
Perosphere
Segment by Type
Direct Thrombin Inhibitors
Direct Factor Xa Inhibitors
Segment by Application
Deep Vein Thrombosis (DVT)
Pulmonary Embolism
Acute Coronary Syndrome
Hemodialysis
Others
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Novel Oral AntiCoagulants (NOAC) report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices